🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted #KRAS G12V Xenograft Tumors #AACR24 🎯

Practice-changing paper in @nejm by Mahé Isabelle Marc Carrier API-CAT team proves that apixaban dose can be reduced after 6mo of anticoag rx with no loss of efficacy and less bleeding. Congrats to the team! nejm.org/doi/full/10.10…

Identification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma Journal of Clinical Investigation 👉targeting the FGFR2 extracellular domain 👉synergy with FGFR inhibitors & activity against kinase domain mutations 🧐Exciting to see evolving options in BTC

Congratulations ⁦Anirban Maitra⁩ and ⁦Linghua Wang, MD, PhD⁩ and team for this tour de force paper just out today in Nature! What an incredible resource for understanding PDAC biology and TME ⁦⁦MD Anderson Cancer Center⁩ nature.com/articles/s4158…

We map the remarkable heterogeneity in terminal #PancreaticCancer, demonstrating marked inter-patient variations in patterns of dissemination, & intra-patient variations in transcriptomic profiles & lineage states, with the most profound differences observed in Liver v Lung mets.

💉TFOX (=mFLOT) vs FOLFOX in 1L treatment of HER2(-) advanced gastric/GEJ adenoca PRODIGE 51- FFCD-GASTFOX The Lancet Oncology ✅ORR: 62.3% vs 53.4% ✅mPFS: 7.5 vs 6.6 mo, p=0.007 ✅mOS: 15 vs 12.6 mo, p=0.048 🚨G3-4 AE: diarrhoea 15% vs 7%, neuropathy 32% vs 20%, neutropenia 27%

I enjoyed reading/learning about TI-CH paper in ⁦NEJM⁩ =>Tumor-Infiltrating Clonal Hematopoiesis | Work from ⁦⁦Oriol Pich⁩ ⁦Elsa Bernard⁩ Elli Papaemmanuil, PhD, ⁦Charles Swanton⁩ + team! Editorial by ⁦Dana-Farber⁩ Ebert/Weeks nejm.org/doi/full/10.10…

Thanks for having me on the show Manta Cares ! Great to discuss what we know — and what we are still uncovering — about early-onset #ColorectalCancer. Excited about the work Dana-Farber's Young-Onset Colorectal Cancer Center and others are doing to push the field forward!

Excited to attend my first ASCO next week! We will be presenting two studies at the Oral Abstract Session on Prevention, Risk Reduction, and Genetics meetings.asco.org/abstracts-pres… meetings.asco.org/abstracts-pres… Dana-Farber Matt Yurgelun, MD Dana-Farber Division of Population Sciences

📢1L Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mut mCRC BREAKWATER NEJM #ASCO25 ✅EC+mFOLFOX6 vs SoC mOS: 30.3 vs 15.1 months HR: 0.49 (0.38 to 0.63) P<0.001 😮 👉nejm.org/doi/full/10.10… OncoAlert Medical.watch Dr Joseph McCollom DO #cancer #oncology #MedX #CRC

⭐️CASSANDRA phase 3 trial of PAXG vs mFFX in R/BR #PDAC ➡️ 3 yr EFS 31% vs 13%; OS immature ➡️phase2 initially then renamed phase3 ➡️somehow no diff in AEs! ➡️2 consecutive ⬆️ca19.9 =event ? Molecular diff in arms -exciting study- warrants further ix ASCO OncoAlert #ASCO25

#ASCO25 Neoadjuvant or adjuvant in dMMR colon cancer? Looks like we’ll be discussing this at length today. Let’s start with this comparison👇

Structured Exercise after Adjuvant Chemotherapy for Colon #Cancer. nejm.org/doi/full/10.10… NEJM ASCO #ASCO25 #ColonCancer #CancerResearch #ExerciseOncology

CRC staging: AJCC v9 Era Past: “TNM.” Now: “TNDM” staging system, incorporating tumor deposits as independent entity. I like it. Better than N1c grouping-better reflects survival risk. Will be a learning curve though… AJCC v10 prediction: TNDM+ctDNA 🤔

Matterhorn shows statistically significant improvement in event free survival when adding Durva (immunotherapy) to standard chemo in Resectable Gastric and GEJ Cancer (HR 0.71) #Asco25

Sara Khosrowjerdi Char, MD Dana-Farber News shares data showing that a proinflammatory diet is linked to worse survival in patients with stage III resected colorectal cancer. Regular physical activity may help reduce this risk. Kimmie Ng, MD, MPH

Happening tonight: Doctors On Call: a live town hall with leading GI oncologists. Moderated by Dr. Rutika Mehta Featuring Dr. James Cleary & Dr. Jose Pimiento Patients & caregivers welcome! Register now: debbiesdream.org/inspire_events #StomachCancer #GIOncology #CancerSupport

This is incredible: Stem cell therapy is showing real promise for treating Type 1 diabetes

FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b amgen.com/newsroom/press….

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx nature.com/articles/s4146…